HEMATOLOGY

Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.

Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.

During a Targeted Oncology™ Case-Based Roundtable™ event, Doris M. Ponce, MD, and participants discussed treatment goals and management of graft-vs-host disease.

Utilizing the combination of inotuzuamb ozogamicin and low intensity chemotherapy, with or without blinatumoamab, showed promising results, but also an increase of patient deaths during remission.

Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.

Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.

Catherine J. Lee, MD, MS, associate professor of medicine in the Clinical Research Division at Fred Hutchinson Cancer Center in Seattle, Washington, led a live virtual discussion on how to treat patients with chronic graft-vs-host disease (GVHD) and how best to assess the extent of their disease.

The panelists share their insights on the identification of patients at high risk for GVHD.

Dr Chen presents statistics on the incidence of chronic graft versus host disease.

In an interview with Targeted Oncology, George Nahas, DO, discussed relevant research on chimeric antigen receptor therapy, bispecifics, and more that are moving the needle in multiple myeloma research.

The partial clinical hold on the TakeAim Leukemia trial exploring emavusertib in patients with acute myeloid leukemia and myelodysplastic syndrome has been lifted.

During a Targeted Oncology™ Case-Based Roundtable™ event, Danko Martincic, MD, outlined the definition, risk factors, and treatment for patients with tumor lysis syndrome.

Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.

In the first article of this series, Elias Jabbour, MD, gives an overview of myelodysplastic syndrome and discusses the evolving treatment landscape.

In the first installment of this series, Elias Jabbour, MD, provides an overview of myelodysplastic syndrome, discusses the current treatment landscape for lower-risk MDS, and offers insights on factors that influence treatment selection.

A phase 1 study is assessing the safety and tolerability of briquilimab in patients with lower-risk myelodysplastic syndrome.

Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.

Updates to the NCCN guidelines will help clinicians treat their patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric acute lymphoblastic leukemia, and pediatric aggressive mature B-cell lymphomas on high-dose methotrexate.

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.

Following positive data from the phase 3 IMerge study of imetelstat, the FDA has received a new drug submission for the agent for the treatment of patients with relapsed or refractory myelodysplastic syndrome.

Rami Komrokji, MD, discusses the different systems of classifying myelodysplastic syndrome.

OMS906, a MASP-3 inhibitor, demonstrated clinical efficacy in a proof-of-concept study for patients with paroxysmal nocturnal hemoglobinuria, according to an interim analysis presented at the 2023 EHA Congress.

In a phase 3 study, imetelstat has shown prolonged transfusion independence and hemoglobin increase in the relapsed or refractory myelodysplastic syndrome population.

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

The FDA has approved avapritinib for adult patients with indolent systemic mastocytosis based on findings from the phase 2 PIONEER trial.

A phase 3 trial evaluating roxadustat for the treatment of anemia in patients receiving concurrent chemotherapy for non-myeloid malignancies met its primary end point.

The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.

Yazan Samhouri, MD, discusses some of the current research that his team at AHN is working on.

In an interview with Targeted Oncology, Adam J. Olszewski, MD, discussed mosunetuzumab and the rationale and findings of this phase 1b/2 study assessing the agent in elderly patients with diffuse large B-cell lymphoma.

Findings from the COMMANDS study in which luspatercept showed statistically significant and clinically meaningful improvements for patients with low-risk myelodysplastic syndrome, the FDA has set a target action date of August 28, 2023.